Skip to main content
Navigate back to homepage
Open search bar.
Open main navigation menu

Main navigation

  • Study
    UCL Portico statue
    Study at UCL

    Being a student at UCL is about so much more than just acquiring knowledge. Studying here gives you the opportunity to realise your potential as an individual, and the skills and tools to thrive.

    • Undergraduate courses
    • Graduate courses
    • Short courses
    • Study abroad
    • Centre for Languages & International Education
  • Research
    Tree-of-Life-MehmetDavrandi-UCL-EastmanDentalInstitute-042_2017-18-800x500-withborder (1)
    Research at UCL

    Find out more about what makes UCL research world-leading, how to access UCL expertise, and teams in the Office of the Vice-Provost (Research, Innovation and Global Engagement).

    • Engage with us
    • Explore our Research
    • Initiatives and networks
    • Research news
  • Engage
    UCL Print room
    Engage with UCL

    Discover the many ways you can connect with UCL, and how we work with industry, government and not-for-profit organisations to tackle tough challenges.

    • Alumni
    • Business partnerships and collaboration
    • Global engagement
    • News and Media relations
    • Public Policy
    • Schools and priority groups
    • Visit us
  • About
    UCL welcome quad
    About UCL

    Founded in 1826 in the heart of London, UCL is London's leading multidisciplinary university, with more than 16,000 staff and 50,000 students from 150 different countries.

    • Who we are
    • Faculties
    • Governance
    • President and Provost
    • Strategy
  • Active parent page: Population Health Sciences
    • Study
    • Research
    • Institutes and Schools
    • Active parent page: News
    • Events
    • About
    • People

New treatment for brain tumours approved following decades of work

The first ever targeted treatment for brain tumours in children has been approved for NHS patients, following over 20 years of research by a UCL clinician scientist.

26 April 2024

New treatment for brain tumours approved following decades of work

Breadcrumb trail

  • Population Health Sciences
  • News

Faculty menu

  • Current page: All news headlines
  • Around the faculty

Professor Darren Hargrave, who is a researcher at the UCL Great Ormond Street Institute of Child Health and consultant at Great Ormond Street Hospital for Children (GOSH), was the Chair of the TADPOLE-G trial steering group, alongside researchers across the world.

The results of the trial, published in the New England Journal of Medicine and the Journal of Clinical Oncology in 2023*, found that a combination of the drugs Dabrafenib and Trametinib can be effective in treating children with rare brain tumours, called BRAF mutated gliomas.

This week the two drugs, which are already used to treat some adult cancers, have been approved by the National Institute for Health and Care Excellence (NICE). This means they will be available as part of standard care for NHS patients, rather than just those on a clinical trial.

For children with paediatric low-grade gliomas, the normal course of treatment is either full surgical removal if possible or additional treatments like chemotherapy and radiotherapy. The low-grade glioma trial showed that the combination of Dabrafenib and Trametinib was four times more effective than chemotherapy and had half the side effects.

Meanwhile, children with high-grade gliomas after surgery require both radiotherapy and chemotherapy. Unfortunately, less than 20% of patients respond well to this treatment. But when the children were treated with Dabrafenib and Trametinib in the trial, the response rate increased to 56%.

Professor Hargrave said: “The new combination therapy is an important advancement in the field of paediatric neuro-oncology that offers an alternative to chemotherapy for low-grade gliomas and provides an additional treatment option for relapsed high-grade gliomas, where overall response rates to the current therapy options have been as low as 20% or less.”

The BRAF gene was first discovered in the early 1980s. In 2002, Professor Hargrave was part of the Cancer Genome Project at the Wellcome Sanger Institute that identified BRAF mutations in human cancer.

Over the next eight years, multiple studies showed how the same mutations could also occur in childhood cancer.

In 2011, Professor Hargrave began working with pharmaceutical companies to design a clinical trial to target these mutations with Dabrafenib and Trametinib.

The first trials for the drugs began at GOSH in 2013 and the international TADPOLE-G study launched five years later – with final results published in 2023.

Professor Hargrave said: “As I was involved in the original study that identified the role of BRAF in cancer and the clinical trails that led to the NICE approval of targeted therapies for childhood brain tumours with BRAF gene mutations, it is exciting to see these treatments becoming available to patients in England and Wales.”

* https://www.ucl.ac.uk/news/2023/nov/clinical-trial-results-give-new-hope-children-rare-gliomas

Links

  • Research in The New England Journal of Medicine
  • Professor Darren Hargrave's academic profile
  • UCL Great Ormond Street Institute of Child Health
  • UCL Population Health Sciences

Image

  • Credit: kritdarat Atsadayuttmetee on iStock

Media contact 

Poppy Tombs 

E: p.tombs [at] ucl.ac.uk

ich-front

UCL Great Ormond Street Institute of Child Health

Further information

  • About Us
  • Athena SWAN
  • Strategic Partners
  • Support Us

Contact

  • People
  • Contact Us

Follow us: 

Tweets by @UCLchildhealth

UCL footer

Visit

  • Bloomsbury Theatre and Studio
  • Library, Museums and Collections
  • UCL Maps
  • UCL Shop
  • Contact UCL

Students

  • Accommodation
  • Current Students
  • Moodle
  • Students' Union

Staff

  • Inside UCL
  • Staff Intranet
  • Work at UCL
  • Human Resources

UCL social media menu

  • Link to Soundcloud
  • Link to Flickr
  • Link to TikTok
  • Link to Youtube
  • Link to Instagram
  • Link to Facebook
  • Link to Twitter

University College London, Gower Street, London, WC1E 6BT

Tel: +44 (0) 20 7679 2000

© 2025 UCL

Essential

  • Disclaimer
  • Freedom of Information
  • Accessibility
  • Cookies
  • Privacy
  • Slavery statement
  • Log in